Loading…
Corcept Therapeutics Incorporated is projected to rise to $142.58 by 2027, a +21% move from its current price of $118.32. CORT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $113.34 | $118.48 | $123.86 | +0.14% |
| Aug 2 | $111.42 | $118.64 | $126.33 | +0.27% |
| Aug 3 | $110.01 | $118.80 | $128.30 | +0.41% |
| Aug 4 | $108.86 | $118.96 | $130.01 | +0.54% |
| Aug 5 | $107.87 | $119.12 | $131.56 | +0.68% |
| Aug 6 | $107.00 | $119.29 | $132.99 | +0.82% |
| Aug 7 | $106.21 | $119.45 | $134.33 | +0.95% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $106.21 | $119.45 | $134.33 | +0.95% |
| Week 2 | $102.13 | $120.58 | $142.37 | +1.91% |
| Week 3 | $99.33 | $121.73 | $149.20 | +2.89% |
| Week 4 | $97.17 | $122.89 | $155.43 | +3.87% |
| Week 5 | $95.41 | $124.06 | $161.32 | +4.85% |
| Week 6 | $93.93 | $125.25 | $167.00 | +5.85% |
| Week 7 | $92.67 | $126.44 | $172.52 | +6.86% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease.
The company was incorporated in 1998 and is headquartered in Redwood City, California.
Corcept Therapeutics Incorporated (CORT) is a healthcare company with a current price of $118.32 and a market capitalization of $12.79B. It is ranked 734 by market cap. The stock sits within a price framework that analysts forecast to rise over time, with the 2026 average price at $118.32 and a trajectory toward higher targets in subsequent years.
The 30-day forecast hints at continued upside potential, with substantial gains implied by the long-run targets.
A major floor 71.6% below — a decisive break under it would weaken the trend.
The nearest floor, 32.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 21.8% above — clearing it would confirm fresh momentum.
Key CORT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CORT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $98.39 | Buy | $101.63 | Buy |
| MA 10 | $95.72 | Buy | $97.41 | Buy |
| MA 20 | $93.34 | Buy | $93.31 | Buy |
| MA 50 | $82.62 | Buy | $82.75 | Buy |
| MA 100 | $62.95 | Buy | $72.02 | Buy |
| MA 200 | $61.59 | Buy | $65.79 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 76.57 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 487.26 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.94 | Buy |
| ROC (12) | 30.78 | Buy |
| Bollinger %B (20,2) | 1.50 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.72 | Buy |
| Awesome (5,34) | 9.04 | Buy |
| Ultimate (7,14,28) | 73.44 | Sell |
| Momentum (10) | 28.60 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 100.54 | Buy |
| ADX (14) | 37.34 | Buy |
| ATR (14) | 3.99 | Info |
In the near term, the stock shows a bullish technical posture. The 30-day range runs from $88.30 to $158.54, signaling upside room above current levels. The RSI is 80, suggesting strong momentum, while the 50-day simple moving average stands at $82.62 and the 200-day simple moving average at $61.59.
Key support is positioned at $79.71 and resistance at $118.32, framing a constructive short-term setup.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $32.15 | $118.32 | $185.25 | 0% | Neutral | |
| $107.23 | $142.58 | $203.84 | +21% | Bullish | |
| $116.32 | $162.47 | $245.67 | +37% | Bullish | |
| $148.79 | $216.60 | $341.90 | +83% | Bullish | |
| $187.55 | $283.35 | $463.47 | +139% | Bullish | |
| $217.46 | $340.02 | $573.51 | +187% | Bullish | |
| $226.61 | $365.98 | $634.37 | +209% | Bullish | |
| $240.36 | $400.36 | $711.17 | +238% | Bullish | |
| $244.16 | $418.95 | $761.03 | +254% | Bullish | |
| $241.23 | $426.04 | $790.03 | +260% | Bullish | |
| $365.94 | $740.59 | $1,495.37 | +526% | Bullish | |
| $961.51 | $2,136.70 | $4,867.37 | +17.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $32.15 | $118.32 | $138.49 | +0.00% |
| August 2026 | $105.17 | $125.08 | $153.43 | +5.71% |
| September 2026 | $111.02 | $133.88 | $167.75 | +7.03% |
| October 2026 | $110.24 | $134.41 | $171.24 | +0.40% |
| November 2026 | $109.62 | $134.90 | $174.17 | +0.36% |
| December 2026 | $114.23 | $141.76 | $185.25 | +5.09% |
Click any year to see its month-by-month CORT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, CORT is projected to trade between $32.15 and $185.25, averaging $118.32 — a potential gain of 0% from today's $118.32. A consolidation phase looks the most probable path here.
Corcept Therapeutics Incorporated's 2027 outlook centres on $142.58, within a $107.23 to $203.84 range. That is up +21% on the projected 2026 average. That marks a +21% change versus current levels. Momentum favours further upside here.
By 2028, CORT could reach as high as $245.67, with a base case around $162.47 and support toward $116.32 — roughly +37% from $118.32. Buyers look set to stay in control over this stretch.
Expect CORT to range from $148.79 to $341.90 through 2029. The $216.60 average target implies a +83% move from current prices. That is up +33% on the projected 2028 average. Momentum favours further upside here.
The CORT price prediction for 2030 points to an average of $283.35 (low $187.55, high $463.47) — a potential gain of +139% on today's $118.32. Buyers look set to stay in control over this stretch.
In 2031, CORT is projected to trade between $217.46 and $573.51, averaging $340.02 — a potential gain of +187% from today's $118.32. That is up +20% on the projected 2030 average. Momentum favours further upside here.
Corcept Therapeutics Incorporated's 2032 outlook centres on $365.98, within a $226.61 to $634.37 range. That is up +8% on the projected 2031 average. That marks a +209% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, CORT could reach as high as $711.17, with a base case around $400.36 and support toward $240.36 — roughly +238% from $118.32. Momentum favours further upside here.
Expect CORT to range from $244.16 to $761.03 through 2034. The $418.95 average target implies a +254% move from current prices. That is up +5% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The CORT price prediction for 2035 points to an average of $426.04 (low $241.23, high $790.03) — a potential gain of +260% on today's $118.32. Momentum favours further upside here.
In 2040, CORT is projected to trade between $365.94 and $1,495.37, averaging $740.59 — a potential gain of +526% from today's $118.32. That is up +74% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Corcept Therapeutics Incorporated's 2050 outlook centres on $2,136.70, within a $961.51 to $4,867.37 range. That is up +189% on the projected 2040 average. That marks a +17.1x change versus current levels. Momentum favours further upside here.
Investing $1,000 in CORT today (≈ 8.451657 CORT) could be worth
$18,058.63
+$17,058.63 (+1706%) by 2050 · US Dollar
Based on the average projected CORT price of $2,136.7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CORTwould be worth at today's price.
$1,000 invested in CORT on Jul 30, 2025 (≈ 14.304105 CORT) would be worth
$1,692.46
+$692.46 (+69.2%) today · 1.69× · US Dollar
Based on a CORT entry price of $69.91 vs. today's $118.32.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $96.66 | $1,224.08 | +22.4% |
| 1 month ago | $86.95 | $1,360.78 | +36.1% |
| 3 months ago | $51.42 | $2,301.05 | +130.1% |
| 6 months ago | $39.87 | $2,967.64 | +196.8% |
| 1 year ago | $69.91 | $1,692.46 | +69.2% |
| All time (5.0y) ago | $21.02 | $5,628.92 | +462.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CORT forecast.
Our base-case forecast reaches $240.00 around 2030.
Implied market cap at $240.00: $25.94B
The multi-year forecast outlines a pronounced upside path. For 2026 the avg target is $118.32, with a min of $32.15 and a max of $185.25, and an ROI of 0%. By 2027 the avg target rises to $142.58 with ROI 20.5 and bullish sentiment, continuing to 2028 with an avg of $162.47 and ROI 37.3, and to 2029 with an avg of $216.60 and ROI 83.1.
In 2030 the avg target is $283.35, the min $187.55, the max $463.47, and ROI 139.5, with a bullish outlook. The path extends to 2040 (avg $740.59, min $365.94, max $1,495.37, ROI 525.9) and 2050 (avg $2,136.70, min $961.51, max $4,867.37, ROI 1705.9), both labeled bullish. These figures illustrate substantial long-run upside potential accompanied by rising price targets and high-end outcomes, though they are not guarantees and reflect a range of possible results.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $283.35, a min of $187.55, and a max of $463.47, with a ROI of 139.5% and a bullish sentiment.
The forecast shows bullish sentiment in successive years, with increasing avg targets and rising ROIs—from 20.5% in 2027 to 83.1% in 2029, up to 139.5% in 2030, then 525.9% in 2040 and 1705.9% in 2050.
No. The 2030 max target is $463.47, which is below $500.
The 30-day range is $88.30 to $158.54.
Current price is $118.32 and market cap is $12.79B.
Corcept Therapeutics Incorporated Community Discussion
0Share your Corcept Therapeutics Incorporated price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.